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Abstract: The application of gold in medicine is can be traced back several thousand years and Au(i) compounds 
have been used in the treatment of rheumatoid arthritis since the last century. Recently research into gold-based 
drugs for a number of human diseases has seen a renaissance due to their markedly different modes of action 
with respect to the classical platinum chemotherapeutic compounds. Within this research area, organometallic 
gold complexes have been particularly explored, mainly due to their higher stability in physiological conditions 
guaranteed by the presence of a direct Au–C bond. Thus, a number of compounds have been tested for their 
uses as anticancer, antibacterial, antiprotozoal as well as anti-HIV agents. In this review a selection of the main 
results obtained on the synthesis, chemical properties and biological activities of two of the most explored 
families of organometallics – Au(i) N-heterocyclic carbenes (NHCs) and cyclometalated Au(iii) compounds – are 
summarized. Their structure–activity relationships and modes of action at the cellular level are also discussed, 
which constitute the basis for future drug design.
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1. Introduction
The discovery of the bacteriostatic
properties of gold cyanide, K[Au(CN)
2
], 
by Robert Koch in 1890 against tubercle 
bacillus was the beginning of the use of gold-
based compounds in modern medicine. In 
the belief that rheumatoid arthritis was 
an atypical form of tuberculosis, the use 
of gold(i) salts was also proposed for the 
treatment of this disease. By the early 
1930s, gold therapy (chrysotherapy) was 
discontinued as a treatment of tuberculosis 
based on its ineffectiveness; however, it is 
still widely used for the management of 
rheumatoid arthritis.
In recent years, gold compounds 
have found clinical relevance as anti-
rheumatic drugs in the form of auranofin 
([triethylphosphine(2,3,4,6-tetra-O-
acetyl-β-1-d-(thiopyranosato-S)Au(i)]), 
Riduara™), aurothioglucose (Solganol™) 
and aurothiomalate (Myochrisine™ or 
Aurolate™) (Fig. 1). The success of the 
platinum(ii) complex cisplatin and deri-
vatives in cancer chemotherapy, also 
stimulated interest in development of 
gold-based cytotoxic agents which has 
yielded extensive research into this field. 
Thus, the established antiarthritic drug 
auranofin was recently repurposed for 
its anticancer properties and is currently 
undergoing evaluation in three distinct US 
clinical trials.[1] To a lesser extent, gold 
compounds have also been evaluated as 
antimicrobial,[2] anti-malarial[3] and anti-
HIV agents.[4]
Concerning Au(i) compounds, aura-
nofin was initially found to be cytotoxic 
towards tumor cells in vitro, leading to 
the identification of other Au(i) phos-
phines with marked antitumor acti vity.[5] 
Among the various examples, bis-che-
lated Au(i) diphosphine complexes of 
the type [AuI(dppe)
2
]Cl (dppe = bis 
(diphenylphosphino)ethane) were patented 
for therapeutic uses by Berners-Price et al. 
in 1986.[6] Despite their relatively good 
stability in physiological conditions, it 
was soon clear that more efforts should 
have been spent to modulate the reactivity 
of these Au(i) complexes for biomedical 
applications, including their selectivity to 
cancer cells.
Au(iii) compounds as anticancer agents 
appeared to be a logical step forward 
from platinum(ii)-based compounds, 
since gold(iii) is isoelectronic (d8) and 
isostructural to platinum(ii) featuring the 
same square-planar geometry. However, 
numerous studies have shown that anti-
cancer gold compounds target other 
biomolecules and biological pathways 
with respect to Pt(ii) complexes.[7] As 
Au(iii) is easily reduced to more stable 
Au(i)/Au(0) species, Au(iii) complexes 
are generally strongly oxidizing agents. 
Reductions can be easily driven by thiols 
groups of biological systems, making 
Au(iii) potentially toxic.[8] Therefore, 
Au(iii) complexes were long believed not 
to be suitable for medicinal applications. 
In this context, organometallic  chem-
istry offers a convenient way for the 
stabilization of the Au(i)/(iii) center 
and ‘fine-tuning’ of the complexes’ 
physiochemical properties via the 
establishment of a direct metal–carbon 
bond. Thus, different families of 
organometallic gold complexes, including 
N-heterocyclic carbenes (NHCs) and
cyclometallated compounds, have been
explored for biological applications.
Moreover, also alkyne gold(i) complexes
Fig. 1. Structures of 
Au(i) anti-rheumatic 
drugs.
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such as viability and proliferation.[21] 
Interestingly, TrxR is able to reduce diffe-
rent protein substrates and low molecular 
weight molecules, in addition to the natural 
substrate thioredoxin. Both TrxR and Trx 
appear overexpressed in certain cancer 
types,[22] leading to the assumption that 
the thioredoxin system exerts a crucial 
role in tumor onset and progression. In 
fact, both enzymes are considered as likely 
‘druggable’ targets anticancer treatment.[23]
2.1 Anticancer Agents
Due to the presence of NHC ligands, 
gold(i) NHC complexes show high 
stability in physiological conditions and 
ease of derivatization, allowing adjustment 
of their physicochemical properties. 
A first study by Berners-Price et al. 
appeared in 2006, where the synthesis, 
characterization and antimitochondrial 
activity of a family of cationic, linear 
two-coordinate [(R
2
Im)
2
Au]+ (Im = 
dialkylimidazol-2-ylidene) complexes 
of monodentate dialkylimidazol-2-yli-
dene ligands were reported, where the 
compounds’ lipophilicity was fine-tuned 
by variation of the substituents (R) on the 
imidazolium salt precursor.[24] The results 
show correlation between the hydrophilic/
lipophilic properties of the complexes 
and their ability to cause mitochondrial 
membrane permeabilization in isolated rat 
liver mitochondria.
The [(R
2
Im)
2
Au]+ complexes were 
synthesized by reacting (Me
2
S)AuCl with 
excess of the appropriate imidazol-2-
ylidene, prepared in situ by deprotonation 
of the imidazolium salt with lithium 
bis(trimethylsilyl)amide (LiHMDS) in 
DMF at room temperature (Scheme 1). 
Of note, to influence the lipophilicity of 
the resulting Au-NHC complexes, the 
alkyl groups of the imidazolium salt were 
systematically varied.
Compounds 1·Br and 3–6·Cl induced 
dose-dependent (µM range), Ca2+-sensi-
tive mitochondrial swelling, with the most 
lipophilic compounds being the most 
active. Cyclosporin A, the benchmark 
inhibitor of the mitochondrial permeability 
transition pore, completely quenched the 
swelling induced by the gold complexes.
More recently, Ott and co-workers 
reported the Au(i) complex 7 (Fig. 2), 
based on an aminotriazole NHC ligand, 
imidazolium salts, by appropriate external 
base, produce metal NHC complexes, 
stabilized through a ‘push-pull’ mechanism 
and that are synthesized in different ways, 
with transmetalation being one of the most 
convenient, overcoming the difficulties of 
unstable free heterocyclic carbenes isolation. 
Thus, the use of silver carbene complexes as 
carbene transfer reagents for the synthesis 
of other metal NHC complexes, including 
Au(i) NHCs is very common.
Below, we will provide an overview of 
the most representative Au(i) NHC scaffolds 
for different therapeutic applications and 
will summarize the knowledge on their 
respective proposed modes of action. 
Since their discovery as antiproliferative 
agents, various experiments on cancer cells 
revealed a variety of effects of Au(i) NHCs 
on cellular metabolism, including strong 
increase of ROS formation and reduced 
mitochondrial activity, finally resulting in 
apoptotic cell death. Notably, most of these 
effects could be attributed to the strong and 
selective inhibition of the seleno-enzyme 
thioredoxin reductase (TrxR) by Au(i) 
NHC complexes.[15]
Thioredoxin reductases (EC 1.8.1.9) 
are homodimeric flavoproteins catalyzing 
the NADPH-dependent reduction of thio-
redoxin (Trx), which is the major protein 
disulfide reductase in cells.[16] TrxRs 
belong to the pyridine nucleotide-disulfide 
oxidoreductase family such as glutathione 
reductase, lipoamide dehydrogenase and 
trypanothione reductase. Thus, they form 
homodimers with each subunit featuring 
a redox-active disulfide bond and a bound 
FAD molecule. 
Mammalian TrxRs possess a conserved 
-Cys-Val-Asn-Val-Gly-Cys- catalytic site, 
which is also found in human glutathione 
reductase (GR), located in the FAD-bin-
ding domain of the enzyme, and a NADPH 
binding site. Moreover, they contain a 
selenocysteine residue at the C-terminal 
active site that is crucial for catalysis[17] 
and that distinguishes them from GR 
or E. coli TrxR.[18] The redox active site 
is located on a flexible arm, solvent-
exposed and reactive towards electrophilic 
agents,[19] constituting an ideal target for 
the development of selective enzyme 
inhibitors, also based on gold, preferentially 
binding selenol groups.[20] The thioredoxin 
system regulates crucial cell functions 
were designed and tested for their anti-
cancer properties, although so far they 
are much less represented.[9] Very recen-
tly, Laguna and co-workers reported on 
the synthesis of complex [Au(C≡CCH
2
Spy-
ridine)(PTA)] (PTA = 1,3,5-triaza-7-phos-
phaadamantane) which was tested for its 
anticancer activity in vitro and in vivo.[10] 
When this derivative is administered by 
intraperitoneal injection in athymic nude 
mice inoculated with HTC-116-luc2 (colon 
cancer), cells, it prolongs their survival and 
displays moderate inhibition of the tumor 
growth with no subsequent organ damage 
after treatment.
Metal–NHC compounds have been 
widely used for catalysis due to their 
strong σ-donor properties, which, together 
with the strength of the metal–NHC 
bond, make such compounds resistant 
towards oxidation and with overall high 
chemical and thermal stability. Some of 
these properties made the research on 
the biological potential of metal–NHC 
complexes as one of the most active areas 
within the field of bioorganometallic 
chemistry. In the past few years, over 100 
reports and more than 350 new transition 
metal complexes containing NHC ligands 
as potential anti-tumor metallodrugs were 
reported.[11]
Concerning cyclometalated complexes, 
numerous ligand systems utilizing different 
donor atoms have been described, which 
were able to stabilize the Au(iii) center.[12] 
Cyclometalation reactions producing five-
membered ring products are very favo-
rable, being performed at room tempera-
ture with a variety of substrates, such as 
amines, imines, 2-phenylpyridines, ben-
zo [h]quinones, other nitrogen donor li-
gands, oxygen-containing compounds, 
phos phorus and sulfur donors etc. Thus, 
a consistent number of reports includes 
these families of complexes.[13]
Here, we will include representative 
examples of the above-mentioned fami-
lies of NHC and cyclometalated gold 
complexes, focusing on those displaying 
most promising biological effects inclu-
ding as anticancer agents, as well as anti-
bacterial and antiviral compounds. We 
refer the reader to more extensive reviews 
for deeper insights into the field.[11,14]
2. Gold(i) N-Heterocyclic Carbene 
Complexes
N-heterocyclic carbenes (NHCs) are 
defined as singlet-carbenes containing a 
divalent carbenic carbon with nitrogen atom 
in the heterocycle.[13] The development 
of stable metal NHC complexes has 
attracted increasing attention in research of 
metallopharmaceuticals. NHCs originated 
from the deprotonation of 1,3 di-substituted 
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Scheme 1. Synthesis of Au(i) NHC complexes as reported in ref [24].
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Au(i)-NHC complexes via different 
methods.[30] Interestingly, some of them 
bear a pentafluorophenolic ester group as 
a possible ‘activable’ moiety for further 
functionalization. This group allowed 
an alkyl amine ligand or other Au(i)-
phosphine complex (10, Fig. 2) to be 
tethered via microwave activation. The 
obtained compounds have shown promising 
antiproliferative effects in human ovarian 
cancer A2780 cells, with respect to non-
tumorigenic ones (HEK-293T). In addition, 
the same authors also synthesized some 
homo- and hetero-bimetallic complexes 
(Au(i)/Au(i) or Au(i)/Cu(ii), Au(i)/Ru(ii), 
respectively) based on the Au(i)–NHC 
scaffold carrying a pentafluorophenol 
ester moiety and another Au(i) phosphane 
complex or a bipyridine ligand bearing a 
pendant amine function (e.g. 11, Fig. 2).[31] 
These complexes showed moderate anti-
cancer properties against A2780, SKOV-3 
8-ylidene)
2
]+ molecules, re spectively (Fig. 
3). It is worth noting that this bis-carbene 
Au(i) complex is an ideal G4 stabilizer 
being: i) planar, ii) prone to electrostatic 
interactions with negatively charged DNA 
due to its overall positive charge, and 
iii) having two caffeine ligands (guanine 
analogues) able to associate to guanine 
moieties in G4 via π-stacking interactions.
Following the success of the trinuclear 
Pt(ii) compound BBR3464 in clinical 
trials,[29] the concept of multinuclearity 
has also been envisaged with Au(i) and 
Au(iii)-based organometallic compounds. 
In most cases, the polynuclear compounds 
were shown to be potent inhibitors of 
cancer cell proliferation with a significant 
improvement compared with their mono-
nuclear parent complexes.
As an example, Le Gendre and co-
workers recently prepared and structurally 
characterized five neutral or cationic 
via the Ag(i) oxide route.[25] Interestingly, 
the complex triggered cytotoxic effects 
in HT-29 and MDA-MB-231 cancer 
cells, and showed an effective and fast 
cellular accumulation. As other bis-NHCs, 
the compound showed only moderate 
inhibition of TrxR (IC
50
 = 1.2 µM), in line 
with the idea that ligand exchange reactions 
at the Au(i) center should occur to allow 
direct binding to the protein’s active site.
Gandin, Marzano and co-workers also 
developed the Au(i) 1,2,4-triazole based 
NHC complex 8 (Fig. 2) and assessed 
its cytotoxic properties in various human 
cancer cell lines, including cisplatin-
sensitive and -resistant cells.[26] This mono-
NHC Au(i) complex was less effective 
than cisplatin and the corresponding Ag(i)-
NHC and Cu(i)-NHC complexes against 
all tested cancer cell lines. In agreement 
with previous findings, TrxR was potently 
inhibited by 8, with IC
50
 values in the nM 
range after 15 min of incubation.
Gold NHC complexes have recently 
been explored for their interactions with 
non-canonical nucleic acid structures. 
Within this framework, Casini et al. 
reported on a series of caffeine-based 
Au(i)-NHC complexes (9a–h, Fig. 2) 
bearing the methylated caffeine-2-yliene 
ligand. The N7-substituted theophylline 
analogues have been synthesized and tested 
for antiproliferative activities in different 
cancerous and non-tumorigenic cell lines 
in comparison to 1,3-dimethylbenzimi 
dazol-2-ylidene derivatives.[26] Complex 
9b was almost two-fold more potent 
than cisplatin against A2780/R cells with 
low toxicity in non-cancerous HEK cells 
(IC
50
 > 100 µM). Notably, the compound 
was revealed to be scarcely toxic, also 
in healthy tissues ex vivo. Interestingly, 
further mechanistic studies showed that the 
highly selective antiproliferative properties 
of 9b may be due to efficient and selective 
DNA G-quadruplex-binding. Of note, 
molecules that template the formation or 
stabilize the structure of G-quadruplex 
DNA (G4) might lead to development 
of new effective anticancer drugs based 
on selective telomerase inhibition. Con-
cerning other possible target proteins, the 
reported studies showed that 9b is only a 
modest PARP-1 inhibitor (i.e. a poor DDR 
impairing agent).[27]
Further X-ray diffraction studies on the 
adduct of the bis-carbene cationic complex 
[Au(9-methylcaffein-8-ylidene)
2
]+ 9b with 
a model of DNA G-quadruplex (G4, Tel 
23 sequence (5'-TAGGG(TTAGGG)3-3')) 
showed that the compound is able to bind 
the G4 at two distinct sites. In detail, the 
gold compound showed possible binding at 
the 3'-3' (3'end-3'end) site, as well as at the 
5'-5' (5'end-5'end) site.[28] The two binding 
domains, located in the 3'-3' and 5'-5' sites, 
host either one or two [Au(9-methylcaffein-
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Fig. 2. Structure of anticancer Au(i) NHC complexes.
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ies. The complexes were designed con-
sidering the photophysical properties of 
the Ru polypyridyl moiety, and the known 
anticancer activities of both metallic 
units. Interestingly, even though all the 
complexes show characteristics very 
simi lar to those of Ru(bipy)
3
 concerning 
luminescence properties, it should be 
noted that the luminescence quantum yield 
in water increases by about 30% in going 
from the mono-ruthenium complex (ϕ
em
 = 
0.020) to the corresponding Au(i)–Ru(ii) 
complex 15b (ϕ
em
 = 0.026[35]). Moreover, 
the emission maximum of the ruthenium 
precursor (630 nm) is slightly red-shifted 
in comparison with that of 15b (615 nm). 
This shift could be due to solvatochromic 
effects, as a charged imidazolium unit in the 
mononuclear Ru(ii) complex is changed to 
a neutral carbene unit in the Au(i)–Ru(ii) 
derivative. Furthermore, an Au(i)-chlorido 
moiety is coordinated by the carbene, also 
leading to strong changes in the molecule.
Complexes 15a–c showed moderate 
anticancer properties very similar to those 
of Ru(bipy)
3
 in human hepatocellular 
carcinoma (Hep3B) cells, as well as 
modest activities (IC
50
 >10  µM) against 
P. falciparum FcB1-Colombia strain.[35] 
Further biological studies showed that the 
cytotoxic effects in tumor cells probably 
did not result via a DNA-related or an 
antimitochondrial mechanism. Moreover, 
the difference of 20 nm between the 
emission spectra of the Au(i)–Ru(ii) and 
Ru(ii) complexes allowed their uptake in 
cancer cells to be followed via fluorescence 
microscopy. The obtained results suggested 
that Au(i)–Ru(ii) complexes are slowly 
transformed into the corresponding Ru 
complexes by release of Au cations to the 
cells, leading to cell death.
As a most recent example of hetero-
nuclear Au(i)–Fe(ii) derivatives, four Au(i)–
NHC complexes featuring 4-ferrocenyl-
substituted imidazol-2-ylidene ligands 
were investigated for antiproliferative and 
antivascular properties.[36] The compounds 
were active against a panel of seven 
cancer cell lines, including multidrug-
resistant ones, with low micromolar or 
nanomolar IC
50
 (72 h) values, according 
to their lipophilicity and cellular uptake. 
Within this series, the two delocalized 
lipophilic cationic mono- and biscarbene 
complexes acted by increasing the reactive 
oxygen species in two ways: via a genuine 
ferrocene effect and by inhibiting the 
thioredoxin reductase.[36] Both complexes 
gave rise to a reorganization of the F-actin 
cytoskeleton in endothelial and melanoma 
cells, associated with a G1 phase cell cycle 
arrest and a retarded cell migration. They 
proved antiangiogenic in tube formation 
assays with endothelial cells and vascular-
disruptive on real blood vessels in the 
chorioallantoic membrane of chicken 
xenografts).[33] Besides, the complex signi-
ficantly reduced tumor growth in vivo, in 
mice bearing HeLa xenograft and mice 
bearing highly aggressive mouse B16F10 
melanoma without causing mouse death or 
body weight loss. Furthermore, it did not 
show systemic anaphylaxis on guinea pigs 
and did not induce localized irritation on 
rabbits in toxicology studies.
Interestingly, within the scope of 
achieving heteronuclear cytotoxic organo-
metallics, in 2016 Contel et al. described 
a simple and efficient synthetic method 
to obtain Au(i)–NHCs featuring a second 
ancillary ligand (such as phosphanes, 
phosphites, arsines and amines) starting 
from the chlorido precursor by abstraction 
of the chloride with silver perchlorate, 
and subsequent addition of the ancillary 
ligand.[34] This synthetic strategy has been 
successfully applied in the preparation of a 
family of cationic heterobimetallic Au(i)–
Ru(ii) complexes (14a–d, Fig. 2). Of 
note, the new heterometallic compounds 
are soluble in DMSO/H
2
O, DMSO/PBS 
or DMSO/medium (1:99) mixtures at 
micromolar concentrations, relevant for 
biological testing. The bimetallic com-
plexes showed a synergistic effect and 
exhibited higher cytotoxicities than 
their monometallic counterparts against 
renal cancer Caki-1 and colon cancer 
HCT-116 cell lines. Importantly, 14a–d 
are considerably less toxic to the non-
tumorigenic human embryonic kidney 
cell line (HEK-293T) than cisplatin. 
In addition, no interaction between the 
heterobimetallic complexes and plasmid 
(pBR322) DNA was observed and 
complex 14a was more efficient than the 
monometallic complex for the inhibition 
of TrxR in cancer cell extracts.[34]
Gornitzka and co-workers reported 
on the synthesis of three Au(i)–Ru(ii) 
heterobimetallic complexes (15a–c, 
Fig. 2) combining an Au(i)–NHC unit 
and a Ru(bipy)
3
 building block.[35] The 
compounds have been fully characterized 
and evaluated for in vitro cytotoxic, 
antileishmanial, and antimalarial activit-
and A549 cancer cell lines, with the Au-
Cu complex 11 being among the most 
active derivatives. Some compounds in 
this series were potent TrxR inhibitors in 
the nanomolar range in vitro and appeared 
to be toxic against healthy liver tissue at 
concentrations in the low micromolar 
range ex vivo.
Due to the high activity of the Au(i)–
bisNHC complexes and the fact that 
no chiral Au(i)–NHC complexes had 
been tested, Veige, Tan and co-workers 
developed the eighteen-membered chiral 
macrocyclic dicarbene-di-Au complex 
[(µ-diNHC)Au(I)]
2
[OTF]
2
 12 (Fig. 2).[32] 
Interestingly, the enantiopure isomers of 
the ligand precursor provide access to the 
enantiopure versions of the binuclear Au(i) 
metallamacrocycles. Both isomers of 12 
were characterized via different methods 
and displayed moderately cytotoxic to 
both healthy and cancerous lines without 
marked selectivity. Moreover, 12 is capable 
of penetrating the cell membrane already 
after few hours incubation, as shown by 
confocal microscopy, and causes cell death 
via apoptosis, as evidenced by DNA gel 
electrophoresis.[32] 
In 2014, Che et al. developed a 
binu clear Au(i) complex (13, Fig. 2) 
contai ning mixed diphosphine and bis-
(NHC) bridging ligands.[33] The com-
pound showed a favorable stability that 
guarantees efficient TrxR inhibition, 
while preventing inactivation by blood 
thiols. In addition, 13 demonstrated in 
vitro cytotoxic activity towards a panel 
of human cancer cells, including HeLa, 
MCF-7 (breast adenocarcinoma), SUNE1 
(nasopharyngeal carcinoma), H1975 (lung 
adenocarcinoma), and B16F10 (mouse 
melanoma) cells, with IC
50
 values up to 
13.5-fold lower than those of cisplatin. 
Complex 13 also inhibited HeLa cell sphere 
formation in vitro which is an indication 
of the cytotoxic effects of the compound 
in cancer stem cell populations, and 
inhibited angiogenesis in tumor models 
in vivo (reduction of blood microvessels 
in the tumor tissue of mice bearing HeLa 
Fig. 3. Propeller 
organisation of the  
Tel 23 sequence in 
the Tel 23:
[Au(9-methylcaffein-
8-ylidene)2]
+ adduct[28] 
(PDB accession code 
5CCW).
ga
lle
y p
roo
f
96 CHIMIA 2017, 71, No. 3 Bioorganometallic chemistry and mechanisms
eggs.[36] The cationic biscarbene complex 
was also tolerated well by mice where it 
led to a volume reduction of xenograft 
tumors (highly metastatic B16-F10 mouse 
melanoma cells) by up to 80%.
2.2 Antibacterial Agents
Concerning possible applications as 
antibacterial agents, the Youngs research 
group was the first to introduce NHCs 
as carrier ligands for Ag+ in 2004 for 
antibacterial applications. However, over 
the years, much less attention has been 
paid to the development of other metal–
NHC complexes as antibacterial agents 
in comparison to silver complexes.[37] In 
the same year, Cetinkaya et al. studied 
the antibacterial activity of six cationic 
Au(i) NHC complexes,[38] which included 
compounds 16, 17 and 18 (Fig. 4), 
displaying promising antibacterial activity 
in vitro against a series of bacterial strains 
(minimum inhibitory concentrations, 
MIC, in the range 3.1−6.3 µg mL−1). 
Remarkably, the compounds’ activity 
appeared to be strongly determined by the 
type of type of functional groups bound to 
the carrier ligands. 
Afterwards, Ghosh et al. synthesized 
the compound [[1-benzyl-3-tert-butylimi-
dazol-2-ylidene]AuCl] (20, Fig. 4) which 
inhibits the growth of Gram positive 
B. subtilis at a MIC of 15 ± 2.3 µM.[39] 
Interestingly, 20 is ca. two times more 
potent than its Ag(i) analogue 19 (Fig. 4). 
To unravel the mechanism of antimicrobial 
activity of 20, the morphology of the 
Bac. subtilis cells was studied following 
4 h incubation with 4 µM of 20. The 
elongation of the Bac. subtilis cells 
grown in the presence of 20 was observed 
compared with the control cells, suggesting 
that the compound inhibits bacterial 
proliferation by blocking the cytokinesis 
step of cell division. More recently, other 
Au(i) NHC complexes with different 
N-substituents on the benzimidazole and 
bis(iminoacenaphthene) scaffolds showed 
only weak antibacterial activity.[40]
In 2012, Dinda et al. reported on 
the antibacterial activity of pyrazine 
functionalized pincer NHC–Ag(i) and 
NHC–Au(i) complexes against antibiotic- 
resistant human pathogens of both Gram-
positive and Gram-negative bacte ria, 
including their inhibitory effects on biofilm 
formation.[41] In this study, complete 
synthetic and structural studies of Au(i) 
and Ag(i) complexes of 2-(1-methyli-
mi dazolium)pyrimidinechloride, 2,6-bis 
(1-methylimidazol)pyrazinechloride and 
2,6-bis(1-methyl imidazol)pyrazinehexa-
fluorophosphate were reported. Among 
them, the [chloro[2,6-bis(1-methylimida-
zol)pyrazine]Ag(i)], 21 and [chloro[2,6-
bis(1-methylimidazol)pyrazine]Au(i)], 
22 complexes (Fig. 5) were observed 
to possess potent antimicrobial activity 
compared to several conventionally used 
antibiotics.[41] Biofilm formation by Gram-
positive bacteria (Streptococcus mutans) 
and Gram-negative bacteria (E. coli) was 
also inhibited by 21 and 22 causing drastic 
damage to the bacterial cell wall and 
increasing membrane permeability. In 
addition, both compounds strongly bind 
to both Lys and Dap-Type peptidoglycan 
layers, most likely inducing the observed 
damage of the bacterial cell wall.
Very recently, Ott and co-workers 
explored a new series of halogenated mono-
NHC Au(i) complexes of general formula 
NHC-Au(i)-Cl.[42] The compounds showed 
promising activities in cancer cells, and 
the effective inhibition of mammalian 
and bacterial thioredoxin reductases was 
confirmed for all the reported derivatives. 
Interestingly, the determination of anti-
bacterial effects against a panel of Gram-
negative and Gram-positive strains demon-
strated that all gold complexes displayed 
a high activity (low micromolar range) 
towards the Gram-positive bacteria, but 
they were substantially less active against 
the Gram-negative ones.[42] Such a clear 
and consistent selectivity for Gram-posi-
tive strains has not been reported for 
previously investigated gold–NHC com-
plexes. Whereas some complexes of the 
type NHC-Au(i)-Cl had indeed triggered 
much stronger effects in Gram-positive 
bacteria,[40a] this was not the case for 
other structural derivatives like cationic 
biscarbene derivatives.[38b]
2.3 Antimalarial Agents
Malaria is an infectious disease caused 
by protozoan parasites of the genus 
Plasmodium and is still a major cause of 
illness and death in tropical countries.[43] 
Among the species that cause malaria (P. 
falciparum, P. vivax, P. ovale, P. malariae 
and P. knowlesi) P. falciparum causes the 
most serious form of the disease. Malaria 
parasites are transmitted by the bite of an 
infected female mosquito of the Anopheles 
genus. Although numerous advances have 
been made in the treatment of this disease, 
about 3.2 billion people – nearly half the 
world’s population – remain at risk of 
malaria. In 2015 alone, there were 214 
million new cases of the disease and more 
than 400,000 malaria-related deaths.[44] 
Unfortunately, millions of people are still 
not accessing the health services necessary 
to prevent and treat this widespread disease.
In the treatment of malaria, several 
organic compounds have been successfully. 
Among them chloroquine (CQ) is among 
the most widely used antimalarial drug. 
However, due to the emergence and spread 
of CQ-resistant Plasmodium parasites, 
the efficacy of CQ has highly diminished. 
In this context, to obtain improved drugs 
able to overcome CQ resistance, numerous 
metal complexes, including gold(i) and 
gold(iii) compounds, have been designed 
as potential antimalarial agents.[43,45]
As an example of organometallics with 
antimalarial properties, the Au(i) complex 
featuring the ylideneamine functionalized 
heterocyclic ligand – [Au(NO
3
)(1,3-tBuIm- 
2-ylidene)] – was found to be much 
less active than CQ against the 3D7 P. 
Falciparum strain.[46] Similarly, among 
the series of dinuclear Au(i) complexes 
containing bis-NHC ligands, only com-
plex 23 (Fig. 6) manifested moderate 
antiplasmodial activity ( IC
50
 ca. 15 µM) 
against the CQ-resistant P. falciparum 
strain FcM29-Cameroon, but was con-
siderably less effective than CQ (IC
50
 = 
0.445 µM[47]). Other bis-carbene gold(i) 
complexes in this series showed no activity 
(IC
50
 > 39 µM). Conversely, mononuclear 
gold(i) complexes containing nitrogen 
heterocyclic functionalized arms, namely 
Fig. 4. Structures of 
potent Au(i) and Ag(i) 
NHC complexes.
Fig. 5. Structures of dinuclear Au(i) and Ag(i) 
NHC complexes active as antibacterial agents.
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DNA could be observed, both complexes 
led to submicromolar inhibition of 
cysteine protease cathepsin B[49] as well as 
inhibition of TrxR.[50]
In 2005, Messori et al. reported on 
the synthesis of complex 29 featuring a 
dimethybenzyl-pyridine backbone (Fig. 
8).[51] This complex proved to be stable 
under cellular reducing conditions; although 
the cytotoxic activity against ovarian 
cancer cell line A2780 is comparable to 
cisplatin, complex 29 displays significant 
cross-resistance, suggesting a different 
mechanism of action. It was demonstrated 
that 29 selectively inhibits TrxR activity, 
which is hypothesized to be caused by 
binding to (seleno)cysteine residues in 
the active site of TrxR.[52] Further studies 
showed that the hydrolysis product of 29 
is able to disrupt mitochondrial function 
and alter the glycolytic pathway in A2780 
cancer cells, leading to apoptosis.[53]
The cationic complex 30, bearing a 
biguanide moiety, was synthesized by Che 
et al. in 2012 (Fig. 8).[54] By introducing 
the polar biguanide ligand, a water-soluble 
complex was obtained that can form an 
Au(iii)–GSH complex detectable by 
ESI-MS. The complex displays higher 
toxicity than cisplatin against several 
cancer cell lines, such as cervical cancer 
(HeLa) cells. The toxicity of complex 30 
is likely to be caused by swelling of the 
endoplasmic reticulum (ER), as suggested 
by oligonucleotide microarray analysis 
and western blot assays. Irreversible 
ER stress triggers apoptosis, with the 
activation of the canonical mitochondrial 
cell death pathway playing an essential 
role.[55] A structural analogue (31) was 
reported by the same group, also utilizing 
a dimethybenzyl-pyridine C^N backbone 
and a dithiocarbamate ligand.[56] This 
complex selectively inhibits breast cancer 
cells (MCF-7) but is less toxic to non-
tumorigenic immortalized liver cells 
(MIHA). Complex 31 was demonstrated 
to form adducts with cysteine-containing 
peptides and proteins (e.g. deubiquitinases) 
by ESI-MS experiments. Notably, Au(iii) 
C^N complexes bearing a dithiocarbamate 
ligand had been previously demonstrated 
by Contel et al. to cause mitochondrial 
dysfunction induced by reactive oxygen 
species (ROS) and Bax/Bak activation.[57]
Synthesis of the 2-benzylpyridine deri-
vative 32 (Fig. 8) was reported by Cinellu et 
al.[58] already in 1996 by reacting NaHAuCl
4
 
with 2-benzylpyridine in refluxing MeCN/
H
2
O overnight. In 2015 Casini, Cinellu 
et al. synthesized the structural analogue 
by replacing one chlorido ligand in the 
presence of excess KPF
6 
with 1,3,5-triaza-
7-phosphaadamantane (PTA).[59] The 
cytotoxic properties of complex 32 and 
33 against various cancer cell lines such 
as ovarian adenocarcinoma (A2780), 
may be generated by elimination reactions, 
by cycloaddition and by hydrometalation. 
Fig. 7 illustrates a general representation 
of the different classes of cyclometalated 
Au(iii) compounds. 
In the following sections, C^N, 
C^N^N and C^N^C cyclometalated 
Au(iii) complexes will be discussed, and 
several studies report on their stability in 
physiological environment and suitable 
chemicophysical properties for therapeutic 
applications. We have decided to organize 
this section according to the different 
families, and within each section we 
will then summarize and highlight the 
compounds’ biological properties and 
possible applications, mainly as anticancer 
agents.
3.1 C^N Complexes
The class of Au(iii) C^N complexes with 
cytotoxic properties was first introduced 
by Parish et al. in 1996,[48] when a series 
of Au(iii) complexes of the structure 
[(damp)AuX
2
] with a 2[dimethylamino)
methyl]-phenyl (damp) backbone (28) was 
synthesized and characterized (Fig. 8). The 
compounds displayed cytotoxic activities 
comparable to cisplatin against various 
cancer cell lines, with the malonato- and 
acetato-substituted complex being the 
most selective and active of the series in 
vitro, and showing moderate anticancer 
effects in vivo. Interestingly, while only 
minor interactions of the compounds with 
quinoline (24) and bipyridine (25) moieties 
(Fig. 6) displayed significantly enhanced 
antiplasmodial activity (IC
50
 values of 1.1 
and 0.33 µM, respectively).[47]
Interestingly, in the same study, two 
gold(iii) complexes 26 and 27 with 
coordinated bis-NHC ligands (Fig. 6) 
showed only moderate activity against P. 
falciparum strain FcM29 (IC
50
 values of 9 
and 13 µM, respectively).[47]
3. Cyclometalated Gold(iii) 
Complexes
Cyclometalation is a convenient method 
of stabilizing metals in different oxidation 
states. This is particularly useful in the case 
of Au(iii) compounds which are otherwise 
prone to be reduced to their respective 
Au(i) species as well as to colloidal gold. In 
general, cyclometalation is defined as the 
metal mediated C–R bond activation of a 
cyclic organic ligand system. The chelating 
ring consists of a strong, covalent C–M σ 
bond and a coordination D–M bond (D = 
donor atom). These ligands incorporate one 
or more donor atoms (such as O-, N-, P-, 
S- or Se). However, it is worth mentioning 
that a variety of reaction pathways other 
than cyclometalation has been optimized 
to achieve metallacycles, especially 
oxidative addition involving C–X bond 
activation (X = F, Cl, Br, I, etc.) and 
transmetalation. Similarly, metallacycles 
Fig. 6. Antimalarial Au(i) and Au(iii) complexes with N-heterocyclic carbenes.
Fig. 7. General 
representation of 
cyclometalated 
complexes.
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was reported by Che et al. already in 
1998[64] via reaction of K[AuCl
4
] and 
[Hg(C^N^CH)Cl] under reflux in MeCN. 
Substitution of the chlorido ligand of 
complex 36 leads to a number of cationic 
Au(iii)–C^N^C complexes with different 
ancillary ligands (37–40). Complex 37 and 
38, containing non-toxic N-donor ligands, 
display cytotoxic activities similar to 
cisplatin against various cancer cell lines, 
such as HeLa cancer cells.[65] However, 
they do not show cross-resistance with 
cisplatin against nasopharyngeal (NPC) 
cancer cells. Gel-mobility shift assays and 
viscosity analysis show that 37 intercalates 
with DNA, causing DNA elongation. It 
has been reported that DNA intercalators 
enhance the assembly of G-quadruplexes. 
Consequently, the ability of 37 to intercalate 
with DNA and induce the formation of 
intramolecular G-quadruplexes from a 
model oligonucleotide, was examined by 
native polyacrylamide gel electrophoresis 
(PAGE),[65] showing that 37 behaves 
similarly to the classical DNA intercalator 
[Pt(terpy)Cl]+ and could potentially cause 
telomerase inhibition. In addition, by flow 
cytometry analysis in SUNE1 cells, it was 
demonstrated that 37 and 38 target cellular 
DNA via S-phase cell arrest, leading to 
apoptosis. 
As observed in several studies, phos-
phine-containing compounds exhibit 
phos phine ligand-mediated cytotoxicity,[5,66] 
which, in addition to their poor stability 
under physiological conditions and non-
specific binding affinities towards various 
biomolecules, prevent their application as 
anticancer drugs. By introducing the C^N^C 
scaffold, significantly higher complex 
stabilities were obtained. For example, 
complex 39 and its dinuclear analogue 40 
are soluble and stable in aqueous media.
[65] The dinuclear complexes of type 40 
show higher antiproliferative activity 
against various cancer cell lines than their 
mononuclear counterparts, especially for 
n = 3, relating to the cytotoxicity of the 
free 1,2-bis(diphenylphosphino)propane 
(dppp) ligand. In vivo studies in rats with 
liver cancer (HCC) orthografts showed 
that the dppp derivative is a nanomolar 
by introducing the strong Au–C bond in 
the organometallic analogues. Notably, 
the latter reveal a marked redox stability 
even in the presence of effective biological 
reductants such as ascorbic acid and 
glutathione. In comparison to complex 
34, complexes 35a–b showed in general 
rather moderate cytotoxic activity against 
the series of 12 human tumor cell lines. 
However, 35a proved to be particularly 
active against human breast cancer cells 
(401NL), while 35b displayed only scar-
cely selective cytotoxic activity. Mass 
spectrometry studies with model proteins 
(hen egg white lysozyme and horse cyto-
chrome c) indicate that complexes 35a–b 
form monometallic adducts with the 
proteins, preserving the Au(iii) center and 
retaining the multidentate ligand. It appears 
that the complex–protein interaction faci-
litates the cleavage of the oxo-bridge and 
conversion into the more reactive mono-
metallic species. 
 
3.4 C^N^C Complexes
Au(iii) C^N^C complexes with anti-
cancer properties have been explored 
by Che and coworkers (Fig. 10). As 
C^N^C pincer ligands allow the highest 
stabilization of the Au(iii) center among 
the herewith presented ligands, it is not 
surprising that this family makes up the 
majority of the reported cyclometalated 
Au(iii) compounds. 
The Au(iii) complex class utilizing the 
2,6-diphenylpyridine as a C^N^C ligand 
mammary carcinoma (MCF-7) and lung 
carcinoma (A549) were explored. Both 
complexes demonstrate good cytotoxic 
activity, with complex 33 displaying 
higher cytotoxic activity than 32, which 
can probably be attributed to the increased 
water solubility induced by the PTA moiety, 
as well as the overall positive charge of the 
complex. Among the possible mechanism 
of actions, potent inhibition of the zinc-
finger protein PARP-1 was reported, which 
has been already demonstrated for several 
coordination gold(iii) complexes with 
N-donor ligands.[60] 
3.3 C^N^N Complexes
In 2003, Cinellu and coworkers reported 
on the synthesis of the mononuclear 
Au(iii) complex 34 with a dimethylbenzyl-
bipyridine C^N^N backbone (Fig. 9).[61] By 
choosing a OH– ligand in ancillary position 
to the Au(iii) center, good solubility of the 
complex under physiological conditions 
was obtained. Upon reaction with the 
plasma protein bovine serum albumin 
(BSA), tight metal–protein adducts were 
formed. It is believed that binding of 
complex 34 to BSA is achieved via his-
tidine moieties on the protein surface. 
Complex 34 shows higher cytotoxic acti-
vity and selectivity against a series of 12 
human tumor cell lines than cisplatin, 
and inhibition of biomolecular systems, 
such as mammalian target of rapamycin/
rapamycin (mTOR), have been suggested 
as a possible mechanism of action.[62]
Following the above-mentioned trend 
of designing multinuclear complexes, the 
same group reported on the dinuclear, 
oxo-bridged complex variants of general 
formula [(N^N^C)
2
Au
2
(µ-O)][PF
6
]
2
 (35) 
(Fig. 9) and their cytotoxic properties in 
2011.[61] Coordination oxo-bridged Au(iii) 
N^N complexes had been previously 
reported[63] (‘Auoxo’ compounds) showing 
antiproliferative effects toward various 
human cancer cell lines. However, the 
latter compounds displayed the stability 
issue of the Au(iii) center in the reducing 
intercellular milieu, which was overcome 
Au
N
X
X
X= Cl, SCN, OAc
X2= oxalato malonato
28
N
Au
Cl
N
Au
Cl Cl
N
Au
OAc
OAc
29
N
nBu
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HN
N
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NH2
30
N
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31
S
S N(Et)2
32 33
PN
NN
Fig. 8. Au(iii) C^N 
complexes with 
cytotoxic properties.
N
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Fig. 9. Mononuclear 
and dinuclear Au(iii) 
C^N^N complexes.
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membrane channels that facilitate the 
permeation of water and small solutes 
across membranes, driven by osmotic or 
solute gradients, with numerous roles in 
physiology. In fact, AQPs are essential 
proteins involved in crucial metabolic 
processes and expressed in several tissues. 
Most importantly, their selective inhibition 
by either small compounds or biologicals 
constitute a realistic opportunity for thera-
peutic applications and/or methods for 
diagnosis and treatment of aquaporin 
related disorders, including cancer.[73]
In terms of possible chemical modi-
fications, the use of carboxylic acid and 
alkyne functionalized Au(i)–NHC com-
plexes for biomolecule conjugation is 
promising to develop organometallic gold 
scaffolds for biomedical applications. 
Similarly, the opportunity to derivatize the 
complexes with groups increasing their 
water solubility (e.g. COOH, OH, sugars, 
etc.) is worth exploring, although this may 
also limit their cellular uptake. 
In general, exploration of the cellular 
uptake, subcellular distribution, as well 
as the fate of these metallodrugs (mono- 
or poly-nuclear) inside cells is of major 
importance to gain insight into their 
mechanism of action. Thus, there is an 
increasing need for imaging methods 
that allow the direct mapping of the 
subcellular distribution of metal-based 
therapeutics, while preserving important 
morphological information of the cell. 
The fluorescence properties with which 
certain metal complexes are endowed are 
certainly attractive to achieve their imaging 
in biological environments.[74] As an 
example, cytotoxic Au(i)–NHC complexes 
bearing a fluorescent anthracenyl ligand[75] 
or Au(i)–NHC[76] compounds bound to 
a coumarin moiety were designed and 
has shown that the redox metabolism 
and mitochondria are the likely cellular 
targets for several metal-based inorganic 
compounds, capable of inducing oxidative 
stress, such as the above-mentioned gold-
based complexes. Within this framework, 
the selenoprotein thioredoxin reductase, 
playing a crucial role in maintaining the 
intracellular redox homeostasis, consti-
tutes a major pharmacological target for 
gold compounds, with high affinity for 
protein selenol and thiol groups. Indeed, it 
is recognized that TrxR inhibition by gold 
compounds triggers severe mitochondrial 
deregulation eventually leading to cell 
apoptosis. 
Certainly, other physiological targets 
other than TrxR should be studied in 
more detail for organometallic gold 
complexes in the future. For example, 
therapeutically relevant zinc finger (ZF) 
proteins have recently been reported to be 
potently targeted by classical coordination 
metal compounds, including Au(i) and 
Au(iii) complexes.[60a] While Au(i) NHC 
complexes were revealed to be only 
moderate inhibitors of these proteins,[27] 
cyclometallated Au(iii) compounds may 
be better candidates. It is worth mentioning 
that the hypothesized mechanism of 
inhibition displacement of Zn2+ from the 
ZF peptide by gold ions leads to decreased 
protein activity, and to formation of the 
so-called ‘gold-finger’ (GF) domain.[71] 
So far, the reported results suggest that 
GF formation by Au(iii) complexes leads 
to the strongest alteration of the native 
ZF structure responsible for protein 
inactivation.
Moreover, among the most intriguing 
protein targets for coordination Au(iii) 
complexes, the aquaporins (AQPs) have 
been recently highlighted.[72] AQPs are 
inhibitor of TrxR1 and induces ER stress, 
while being scarcely reactive with DNA.[67]
By replacing the PPh
3
 moiety with a 
NHC ligand complexes 41 and 42 – mono- 
and dinuclear compounds, respectively – 
can be obtained,[68] resulting in the reduction 
of the cytotoxic activity and selectivity 
of the compounds, supporting the fact 
that indeed phosphine ligand-mediated 
cytotoxicity is crucial for complexes 39 
and 40. In this case, the mononuclear 
complex 41 displays higher cytotoxic 
activity than its dinuclear analogue 42, 
being 167-fold more cytotoxic to non-
small lung carcinoma cells (NCI-H460) 
than to normal lung fibroblast cells (CCD-
19Lu). DNA interaction studies showed 
that complex 41 induces DNA strand 
breaks and subsequent cell death through 
the stabilization of TopoI-linked DNA.[69]
Interestingly, a recent development in 
the field of Au(iii) C^N^C complexes is 
the discovery of supramolecular poly mers, 
self-assembled from cyclometalated Au(iii) 
C^N^C complexes. In this frame work, 
the mononuclear complex [Au(C,N,C) 
(4-dpt)]+ (4-dpt = 2,4-diamino-6-(4-
pyridyl)-1,3,5-triazine) 43 (Fig. 10) 
was chosen by Che et al. due to the 
ability of the antiangiogenic 4-dpt ligand 
to form intramolecular hydrogen bonds 
and to establish π-π interactions.[70] 
Via transmission electron (TEM) and 
scanning electron microscopy (SEM), 
partially aligned nanofibers with diameters 
and lengths of about 50 nm could be 
demonstrated for 43. Complex 43 displays 
high cytotoxic activity towards murine 
cancer cell line B16 and non-tumorigenic 
lung fibroblast cells (CCD-19Lu). It was 
suggested that the sustained release of free 
4-dpt ligand and simultaneous formation 
of Au(iii)-glutathione adducts account for 
the observed cytotoxicity. GSH adduct 
formation was assessed via ESI-MS and 
UV-VIS for 43 in phosphate-buffered 
saline containing GSH (2 mM), showing 
significant cluster peaks for [(C^N^C)
Au(GSH)]+ and the dimeric species 
[(C^N^C)
2
Au
2
(GSH)
2
]2+. Furthermore, the 
nanofiber network of the polymer could be 
used to encapsulate other cytotoxic agents, 
thus enabling a localized drug delivery 
while reducing side toxicity. 
4. Conclusions and Perspective 
Nowadays, gold compounds constitute 
an important class of promising cytotoxic 
agents which could be optimized to target 
cancer cells, provided that adequate 
attention in disclosing the effective cellular 
and molecular mechanisms through 
which these compounds induce their 
important antiproliferative effects will 
be dedicated. So far, a number of studies 
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Fig. 10. Au(iii) C^N^C complexes synthesized by Che et al.[70] with different types of ancillary 
ligands.
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